Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Open Access
- 3 March 2016
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 127 (9), 1117-1127
- https://doi.org/10.1182/blood-2015-11-679134
Abstract
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires robust T-cell expansion and engraftment. A T-cell defect in chronic lymphocytic leukemia (CLL) due to disease and/or therapy impairs ex vivo expansion and response to CAR T cells. To evaluate the effect of ibrutinib treatment on the T-cell compartment in CLL as it relates to CAR T-cell generation, we examined the phenotype and function of T cells in a cohort of CLL patients during their course of treatment with ibrutinib. We found that ≥5 cycles of ibrutinib therapy improved the expansion of CD19-directed CAR T cells (CTL019), in association with decreased expression of the immunosuppressive molecule programmed cell death 1 on T cells and of CD200 on B-CLL cells. In support of these findings, we observed that 3 CLL patients who had been treated with ibrutinib for ≥1 year at the time of T-cell collection had improved ex vivo and in vivo CTL019 expansion, which correlated positively together and with clinical response. Lastly, we show that ibrutinib exposure does not impair CAR T-cell function in vitro but does improve CAR T-cell engraftment, tumor clearance, and survival in human xenograft models of resistant acute lymphocytic leukemia and CLL when administered concurrently. Our collective findings indicate that ibrutinib enhances CAR T-cell function and suggest that clinical trials with combination therapy are warranted. Our studies demonstrate that improved T-cell function may also contribute to the efficacy of ibrutinib in CLL. These trials were registered at www.clinicaltrials.gov as #NCT01747486, #NCT01105247, and #NCT01217749.Keywords
This publication has 50 references indexed in Scilit:
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaThe New England Journal of Medicine, 2014
- Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicityBlood, 2014
- PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25ACell Cycle, 2012
- Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell ProliferationScience Signaling, 2012
- CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemiaLeukemia, 2011
- The role of CD200 in immunity to B cell lymphomaJournal of Leukocyte Biology, 2010
- Prognostic importance of T and NK‐cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemiaBritish Journal of Haematology, 2008
- Regulation of Myeloid Cell Function through the CD200 ReceptorThe Journal of Immunology, 2006
- Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 ResponsesThe Journal of Immunology, 2003
- PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosineProceedings of the National Academy of Sciences of the United States of America, 2001